These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 23947935

  • 21. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
    Chiladakis JA, Kalogeropoulos A, Patsouras N, Manolis AS.
    J Am Coll Cardiol; 2004 Aug 18; 44(4):859-63. PubMed ID: 15312872
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter.
    Maykov EB, Yuricheva YA, Mironov NY, Sokolov SF, Golitsyn SP, Rosenshtraukh LV, Chazov EI.
    J Cardiovasc Pharmacol; 2014 Sep 18; 64(3):247-55. PubMed ID: 24785342
    [Abstract] [Full Text] [Related]

  • 23. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
    Hongo RH, Themistoclakis S, Raviele A, Bonso A, Rossillo A, Glatter KA, Yang Y, Scheinman MM.
    J Am Coll Cardiol; 2004 Aug 18; 44(4):864-8. PubMed ID: 15312873
    [Abstract] [Full Text] [Related]

  • 24. Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.
    Page RL, Pritchett EL, Connolly S, Wilkinson WE, SVA-4 Investigators.
    J Cardiovasc Electrophysiol; 2008 Feb 18; 19(2):172-7. PubMed ID: 17916138
    [Abstract] [Full Text] [Related]

  • 25. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H, Brendorp B, Pedersen OD, Køber L, Torp-Petersen C.
    Expert Opin Pharmacother; 2003 Jun 18; 4(6):973-85. PubMed ID: 12783593
    [Abstract] [Full Text] [Related]

  • 26. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH, Pollak A, Singh SN, Friedrich T.
    J Am Coll Cardiol; 1997 Feb 18; 29(2):385-90. PubMed ID: 9014993
    [Abstract] [Full Text] [Related]

  • 27. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar 18; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

  • 28. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
    Abraham JM, Saliba WI, Vekstein C, Lawrence D, Bhargava M, Bassiouny M, Janiszewski D, Lindsay B, Militello M, Nissen SE, Poe S, Tanaka-Esposito C, Wolski K, Wilkoff BL.
    Circ Arrhythm Electrophysiol; 2015 Aug 18; 8(4):772-6. PubMed ID: 26063741
    [Abstract] [Full Text] [Related]

  • 29. [Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter].
    Maykov EB, Yuricheva YA, Mironov NY, Sokolov SF, Golitsyn SP, Rozenshtraukh LV, Chazov EI.
    Ter Arkh; 2015 Aug 18; 87(1):38-48. PubMed ID: 25823268
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study.
    Wells R, Khairy P, Harris L, Anderson CC, Balaji S.
    Pacing Clin Electrophysiol; 2009 Oct 18; 32(10):1313-8. PubMed ID: 19691680
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R, Sami M.
    Can J Cardiol; 2001 Jan 18; 17(1):63-7. PubMed ID: 11173316
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ, Polak PE, van 't Hof A, Rasmussen HS, Dunselman PH, Kingma JH.
    Am J Cardiol; 1992 Feb 01; 69(4):417-9. PubMed ID: 1734660
    [No Abstract] [Full Text] [Related]

  • 35. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G.
    Acta Cardiol; 1995 Feb 01; 50(2):125-34. PubMed ID: 7610735
    [Abstract] [Full Text] [Related]

  • 36. The safety and efficacy of ibutilide in children and in patients with congenital heart disease.
    Hoyer AW, Balaji S.
    Pacing Clin Electrophysiol; 2007 Aug 01; 30(8):1003-8. PubMed ID: 17669084
    [Abstract] [Full Text] [Related]

  • 37. [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
    Trappe HJ, Pfitzner P.
    Med Klin (Munich); 1996 Oct 15; 91(10):617-25. PubMed ID: 9019638
    [Abstract] [Full Text] [Related]

  • 38. Acute management of atrial fibrillation and atrial flutter in the critical care unit: should it be ibutilide?
    Varriale P, Sedighi A.
    Clin Cardiol; 2000 Apr 15; 23(4):265-8. PubMed ID: 10763074
    [Abstract] [Full Text] [Related]

  • 39. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias.
    Kobayashi Y, Atarashi H, Ino T, Kuruma A, Nomura A, Saitoh H, Hayakawa H.
    J Cardiovasc Pharmacol; 1997 Sep 15; 30(3):367-73. PubMed ID: 9300322
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.
    Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C.
    Circulation; 2001 Jul 17; 104(3):292-6. PubMed ID: 11457747
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.